ABSTRACT
Basic hematological features of CEA/ABVD medication for Hodgkin's disease were studied. An effective model was worked out on the principle of data discrimination for predicting different leukocytic toxicities induced by cytostatics-1 administration, once in two weeks. It might predict individual limits (dosage and intervals) of a chemotherapy course unless a colony-stimulation technique is used.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hematologic Diseases/chemically induced , Hodgkin Disease/blood , Hodgkin Disease/drug therapy , Models, Statistical , Adult , Aged , Bleomycin/adverse effects , Carboplatin/adverse effects , Dacarbazine/adverse effects , Discriminant Analysis , Doxorubicin/adverse effects , Drug Administration Schedule , Etoposide/adverse effects , Female , Humans , Male , Middle Aged , Prognosis , Risk Factors , Vinblastine/adverse effectsABSTRACT
A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573). Early-onset radiation-related injuries (pneumonitis) and exposure of lung tissues to radiation were identified as the main risk factors for cardiopathology development. It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology. However, a locally administered TTD ranging 36-44 Gy to deal with residual tumor offers best advantage in preventing local relapse. Nor does it increase the risk of future complications. Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
